[Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
D018849:Controlled Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D000077545:Eplerenone; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy*; D010919:Placebos; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D010919:Placebos; D013148:Spironolactone; D000077545:Eplerenone